IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss TherapiesAccesswire • 11/06/24
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1Accesswire • 10/17/24
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE ChallengeAccesswire • 10/03/24
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentBusiness Wire • 09/18/24
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseBusiness Wire • 09/04/24
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's DiseaseBusiness Wire • 08/22/24
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price TargetBusiness Wire • 07/18/24
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety ProfileBusiness Wire • 07/09/24
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseBusiness Wire • 06/25/24
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 TetrahydrocannabinolBusiness Wire • 06/10/24
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1Business Wire • 05/28/24
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week TwoBusiness Wire • 04/16/24
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockBusiness Wire • 03/26/24
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's AgitationBusiness Wire • 03/20/24
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024Business Wire • 03/20/24
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's PipelineBusiness Wire • 03/12/24
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetBusiness Wire • 02/23/24
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer'sBusiness Wire • 01/23/24
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's TrialBusiness Wire • 01/17/24